Local-regional prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 5, 2008, Pages 516-521

  Jones, Marklyn J ^a   Koeneman, Kenneth S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Locally advanced; Prostate adenocarcinoma; Staging

Indexed keywords

ANDROGEN; DOCETAXEL; ESTRAMUSTINE; LEUPRORELIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; GLEASON SCORE; HORMONAL THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

CLINICAL TRIALS AS TOPIC; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK;

EID: 50649119710     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.03.007     Document Type: Review

References (52)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. American Cancer Society. Cancer facts and figures 2006 (2006), American Cancer Society, Atlanta
3. Miller D.C., Hafez K.S., Stewart A., et al. Prostate carcinoma presentation, diagnosis, and staging: An update from the National Cancer Data Base. Cancer 98 (2003) 1169-1178
4. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172 (2004) 910-914
5. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
6. Perez C.A., Michalski J.M., and Lockett M.A. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: Comparison of American Society of Therapeutic Radiology and Oncology consensus or 1 ng/mL as endpoint. Int J Radiat Oncol Biol Phys 49 (2001) 1287-1296
7. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
8. Robson M., and Dawson N. How is androgen-dependent metastatic prostate cancer best treated?. Hematol Oncol Clin North Am 10 (1996) 727-747
9. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972-3982
10. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
11. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
12. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
13. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
14. Fearn P., and Kattan M.W. Prostate nomogram (2007), Memorial Sloan Kettering Cancer Center. http://www.mskcc.org
15. D'Amico A.V., Schnall M., Whittington R., et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 51 (1998) 449-454
16. Wang L., Mullerad M., Chen H.N., et al. Prostate cancer: Incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232 (2004) 133-139
17. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55 (2000) 572-577
18. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
19. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238 (2006) 597-603
20. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
21. Goluboff E.T., Heitjan D.F., DeVries G.M., et al. Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy. J Urol 158 (1997) 1876-1878 Discussion 1878-9
22. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
23. Berger A.P., Deibl M., Strasak A., et al. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: Results from a screening population. Urology 68 (2006) 1067-1071
24. D'Amico A.V., Hui-Chen M., Renshaw A.A., et al. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 176 (2006) S11-S15
25. Freedland S.J., Dorey F., and Aronson W.J. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 57 (2001) 476-480
26. Thiel R., Pearson J.D., Epstein J.I., et al. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. Urology 49 (1997) 716-720
27. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
28. Moul J.W., Sun L., Hotaling J.M., et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 177 (2007) 499-503
29. Ankerst D.P., and Thompson I.M. Understanding mixed messages about prostate specific antigen: Biases in the evaluation of cancer biomarkers. J Urol 177 (2007) 426-427
30. Patel D.A., Presti Jr. J.C., McNeal J.E., et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157-6162
31. Egawa S., Arai Y., Tobisu K., et al. Use of pretreatment prostate specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3 (2000) S11
32. Sengupta S., Myers R.P., Slezak J.M., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
33. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005-7012
34. Koeneman K.S., Yeung F., and Chung L.W. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39 (1999) 246-261
35. Sikes R.A., Nicholson B.E., Koeneman K.S., et al. Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer 110 (2004) 497-503
36. Khoddami S.M., Shariat S.F., Lotan Y., et al. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumors treated with radical prostatectomy. BJU Int 94 (2004) 42-46
37. Lotan Y., Shariat S.F., Khoddami S.M., et al. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 171 (2004) 2209-2214
38. Shariat S.F., Khoddami S.M., Saboorian H., et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 171 (2004) 1122-1127
39. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
40. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 172 (2004) 2252-2255
41. Pagliarulo V., Hawes D., Brands F.H., et al. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24 (2006) 2735-2742
42. Heidenreich A., Varga Z., and Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 167 (2002) 1681-1686
43. DiMarco D.S., Zincke H., Sebo T.J., et al. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121-1125
44. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
45. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296 (2006) 2329-2335
46. Walsh P.C., DeWeese T.L., and Eisenberger M.A. A structured debate: Immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 166 (2001) 508-515
47. Gao H., Ouyang X., Banach-Petrosky W., et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 101 (2004) 17204-17209
48. Ferrero J.M., Foa C., Thezenas S., et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology 66 (2004) 281-287
49. Gravis G., Bladou F., Salem N., et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 98 (2003) 1627-1634
50. Friedland D., Cohen J., Miller Jr. R., et al. A Phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26 (1999) 19-23
51. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
52. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512